nach oben

Erschienen in:

15.07.2016 | Guideline

Clinical guides for atypical hemolytic uremic syndrome in Japan

verfasst von: Hideki Kato, Masaomi Nangaku, Hiroshi Hataya, Toshihiro Sawai, Akira Ashida, Rika Fujimaru, Yoshihiko Hidaka, Shinya Kaname, Shoichi Maruyama, Takashi Yasuda, Yoko Yoshida, Shuichi Ito, Motoshi Hattori, Yoshitaka Miyakawa, Yoshihiro Fujimura, Hirokazu Okada, Shoji Kagami, The Joint Committee for the Revision of Clinical Guides of Atypical Hemolytic Uremic Syndrome in Japan

Erschienen in: Clinical and Experimental Nephrology | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Atypical hemolytic uremic syndrome (aHUS) is a rare disease characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. In 2013, we developed diagnostic criteria to enable early diagnosis and timely initiation of appropriate treatment for aHUS. Recent clinical and molecular findings have resulted in several proposed classifications and definitions of thrombotic microangiopathy and aHUS. Based on recent advances in this field and the emerging international consensus to exclude secondary TMAs from the definition of aHUS, we have redefined aHUS and proposed diagnostic algorithms, differential diagnosis, and therapeutic strategies for aHUS.

Thompson RA, Winterborn MH. Hypocomplementaemia due to a genetic deficiency of beta 1H globulin. Clin Exp Immunol. 1981;46(1):110–9.PubMedPubMedCentral

Warwicker P, Goodship TH, Donne RL, Pirson Y, Nicholls A, Ward RM, et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int. 1998;53(4):836–44. doi:10.1111/j.1523-1755.1998.00824.x.CrossRefPubMed

Mukai S, Hidaka Y, Hirota-Kawadobora M, Matsuda K, Fujihara N, Takezawa Y, et al. Factor H gene variants in Japanese: its relation to atypical hemolytic uremic syndrome. Mol Immunol. 2011;49(1–2):48–55. doi:10.1016/j.molimm.2011.07.017.CrossRefPubMed

Sawai T, Nangaku M, Ashida A, Fujimaru R, Hataya H, Hidaka Y, et al. Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the Joint Committee of the Japanese Society of Nephrology and the Japan Pediatric Society. Clin Exp Nephrol. 2014;18(1):4–9. doi:10.1007/s10157-013-0911-8.CrossRefPubMed

Sawai T, Nangaku M, Ashida A, Fujimaru R, Hataya H, Hidaka Y, et al. Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the Joint Committee of the Japanese Society of Nephrology and the Japan Pediatric Society. Pediatr Int. 2014;56(1):1–5. doi:10.1111/ped.12274.CrossRefPubMed

Loirat C, Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011;6:60. doi:10.1186/1750-1172-6-60.CrossRefPubMedPubMedCentral

Scully M, Goodship T. How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome. Br J Haematol. 2014;164(6):759–66. doi:10.1111/bjh.12718.CrossRefPubMedPubMedCentral

Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31(1):15–39. doi:10.1007/s00467-015-3076-8.CrossRefPubMed

Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa M, Grinyo JM, et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia. 2013;33(1):27–45. doi:10.3265/Nefrologia.pre2012.Nov.11781.PubMed

10.

Mele C, Remuzzi G, Noris M. Hemolytic uremic syndrome. Semin Immunopathol. 2014;36(4):399–420. doi:10.1007/s00281-014-0416-x.CrossRefPubMed

11.

Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaime F, Dragon-Durey MA, Ngo S, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013;8(4):554–62. doi:10.2215/CJN.04760512.CrossRefPubMedPubMedCentral

12.

Sheerin NS, Kavanagh D, Goodship TH, Johnson S. A national specialized service in England for atypical haemolytic uraemic syndrome-the first year’s experience. QJM. 2015;109(1):27–33. doi:10.1093/qjmed/hcv082.CrossRefPubMed

13.

Hofer J, Janecke AR, Zimmerhackl LB, Riedl M, Rosales A, Giner T, et al. Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2013;8(3):407–15. doi:10.2215/CJN.01260212.CrossRefPubMed

14.

Lemaire M, Fremeaux-Bacchi V, Schaefer F, Choi M, Tang WH, Le Quintrec M, et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet. 2013;45(5):531–6. doi:10.1038/ng.2590.CrossRefPubMedPubMedCentral

15.

Bu F, Maga T, Meyer NC, Wang K, Thomas CP, Nester CM, et al. Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2014;25(1):55–64. doi:10.1681/ASN.2013050453.CrossRefPubMed

16.

Johnson S, Stojanovic J, Ariceta G, Bitzan M, Besbas N, Frieling M, et al. An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome. Pediatr Nephrol. 2014;29(10):1967–78. doi:10.1007/s00467-014-2817-4.CrossRefPubMed

17.

Uemura O, Honda M, Matsuyama T, Ishikura K, Hataya H, Yata N, et al. Age, gender, and body length effects on reference serum creatinine levels determined by an enzymatic method in Japanese children: a multicenter study. Clin Exp Nephrol. 2011;15(5):694–9. doi:10.1007/s10157-011-0452-y.CrossRefPubMed

18.

KDIGO. Clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2:1–138.CrossRef

19.

Kato H, Yoshida Y, Nangaku M. Pathogenesis of complement-mediated and coagulation-mediated atypical hemolytic uremic syndrome. Nihon Jinzo Gakkai Shi. 2014;56(7):1058–66.

20.

Tadakamalla AK, Talluri SK, Besur S. Pseudo-thrombotic thrombocytopenic purpura: a rare presentation of pernicious anemia. N Am J Med Sci. 2011;3(10):472–4. doi:10.4297/najms.2011.3472.CrossRefPubMedPubMedCentral

21.

Fujimura Y, Isonishi A. Pathophysiology of thrombotic thrombocytopenic purpura. Nihon Jinzo Gakkai Shi. 2014;56(7):1043–51.

22.

Shah N, Rutherford C, Matevosyan K, Shen YM, Sarode R. Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP). Br J Haematol. 2013;163(4):514–9. doi:10.1111/bjh.12569.CrossRefPubMed

23.

Hattori M. Pathogenesis and clinical features of HUS and aHUS. Nihon Jinzo Gakkai Shi. 2014;56(7):1052–7.

24.

Lechner K, Obermeier HL. Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases. Medicine (Baltimore). 2012;91(4):195–205. doi:10.1097/MD.0b013e3182603598.CrossRef

25.

von Vigier RO, Seibel K, Bianchetti MG. Positive Coombs test in pneumococcus-associated hemolytic uremic syndrome. A review of the literature. Nephron. 1999;82(2):183–4.CrossRef

26.

Allen U, Licht C. Pandemic H1N1 influenza A infection and (atypical) HUS–more than just another trigger? Pediatr Nephrol. 2011;26(1):3–5. doi:10.1007/s00467-010-1690-z.CrossRefPubMed

27.

Shimizu M, Yokoyama T, Sakashita N, Sato A, Ueno K, Akita C, et al. Thomsen-Friedenreich antigen exposure as a cause of Streptococcus pyogenes-associated hemolytic-uremic syndrome. Clin Nephrol. 2012;78(4):328–31.CrossRefPubMed

28.

Fan X, Yoshida Y, Honda S, Matsumoto M, Sawada Y, Hattori M, et al. Analysis of genetic and predisposing factors in Japanese patients with atypical hemolytic uremic syndrome. Mol Immunol. 2013;54(2):238–46. doi:10.1016/j.molimm.2012.12.006.CrossRefPubMed

29.

Fakhouri F, Roumenina L, Provot F, Sallee M, Caillard S, Couzi L, et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol. 2010;21(5):859–67. doi:10.1681/ASN.2009070706.CrossRefPubMedPubMedCentral

30.

Matsui K, Yasuda T. Drug/transplant-induced atypical hemolytic uremic syndrome. Nihon Jinzo Gakkai Shi. 2014;56(7):1067–74.

31.

Swisher KK, Doan JT, Vesely SK, Kwaan HC, Kim B, Lammle B, et al. Pancreatitis preceding acute episodes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: report of five patients with a systematic review of published reports. Haematologica. 2007;92(7):936–43.CrossRefPubMed

32.

McDonald V, Laffan M, Benjamin S, Bevan D, Machin S, Scully MA. Thrombotic thrombocytopenic purpura precipitated by acute pancreatitis: a report of seven cases from a regional UK TTP registry. Br J Haematol. 2009;144(3):430–3. doi:10.1111/j.1365-2141.2008.07458.x.CrossRefPubMed

33.

Matsumoto M. Pathophysiology and management of transplantation associated TMA. Rinsho Ketsueki. 2013;54(10):1958–65.PubMed

34.

Jodele S, Licht C, Goebel J, Dixon BP, Zhang K, Sivakumaran TA, et al. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood. 2013;122(12):2003–7. doi:10.1182/blood-2013-05-501445.CrossRefPubMedPubMedCentral

35.

Le Quintrec M, Lionet A, Kamar N, Karras A, Barbier S, Buchler M, et al. Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant. 2008;8(8):1694–701. doi:10.1111/j.1600-6143.2008.02297.x.CrossRefPubMed

36.

Verbiest A, Pirenne J, Dierickx D. De novo thrombotic microangiopathy after non-renal solid organ transplantation. Blood Rev. 2014;28(6):269–79. doi:10.1016/j.blre.2014.09.001.CrossRefPubMed

37.

Roumenina LT, Roquigny R, Blanc C, Poulain N, Ngo S, Dragon-Durey MA, et al. Functional evaluation of factor H genetic and acquired abnormalities: application for atypical hemolytic uremic syndrome (aHUS). Methods Mol Biol. 2014;1100:237–47. doi:10.1007/978-1-62703-724-2_19.CrossRefPubMed

38.

Yoshida Y, Miyata T, Matsumoto M, Shirotani-Ikejima H, Uchida Y, Ohyama Y, et al. A novel quantitative hemolytic assay coupled with restriction fragment length polymorphisms analysis enabled early diagnosis of atypical hemolytic uremic syndrome and identified unique predisposing mutations in Japan. PLoS One. 2015;10(5):e0124655. doi:10.1371/journal.pone.0124655.CrossRefPubMedPubMedCentral

39.

Sakai N, Wada T. Therapeutic strategy and thrombotic microangiopathy. Nihon Jinzo Gakkai Shi. 2014;56(7):1082–9.

40.

Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5(10):1844–59. doi:10.2215/CJN.02210310.CrossRefPubMedPubMedCentral

41.

Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368(23):2169–81. doi:10.1056/NEJMoa1208981.CrossRefPubMed

42.

Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 2015;87(5):1061–73. doi:10.1038/ki.2014.423.CrossRefPubMedPubMedCentral

43.

Ito N, Hataya H, Saida K, Amano Y, Hidaka Y, Motoyoshi Y, et al. Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan. Clin Exp Nephrol. 2015;20(2):265–72. doi:10.1007/s10157-015-1142-y.CrossRefPubMed

44.

Nester CM. Managing atypical hemolytic uremic syndrome: chapter 2. Kidney Int. 2015;87(5):882–4. doi:10.1038/ki.2015.60.CrossRefPubMed

Titel: Clinical guides for atypical hemolytic uremic syndrome in Japan
verfasst von: Hideki Kato
Masaomi Nangaku
Hiroshi Hataya
Toshihiro Sawai
Akira Ashida
Rika Fujimaru
Yoshihiko Hidaka
Shinya Kaname
Shoichi Maruyama
Takashi Yasuda
Yoko Yoshida
Shuichi Ito
Motoshi Hattori
Yoshitaka Miyakawa
Yoshihiro Fujimura
Hirokazu Okada
Shoji Kagami
The Joint Committee for the Revision of Clinical Guides of Atypical Hemolytic Uremic Syndrome in Japan
Publikationsdatum: 15.07.2016
Verlag: Springer Japan
Erschienen in: Clinical and Experimental Nephrology / Ausgabe 4/2016
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
DOI: https://doi.org/10.1007/s10157-016-1276-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Clinical guides for atypical hemolytic uremic syndrome in Japan

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2016

Extracapillary proliferation and arteriolar hyalinosis are associated with long-term kidney survival in IgA nephropathy

Enteric-coated mycophenolate sodium in pediatric lupus nephritis: a retrospective cohort study

Role of renin–angiotensin system inhibitors in retardation of progression of end-stage renal failure: a retrospective study

Early response to erythropoiesis-stimulating agents in non-dialysis chronic kidney disease patients

Functional analysis of novel allelic variants in URAT1 and GLUT9 causing renal hypouricemia type 1 and 2

Clinical and genetic characteristics of Japanese nephronophthisis patients

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin